Literature DB >> 20055070

The effect of steroid treatment with inhaled budesonide or intravenous methylprednisolone on phosgene-induced acute lung injury in a porcine model.

Adam Smith1, Roger Brown, Bronwen Jugg, Janet Platt, Thomas Mann, Charles Masey, John Jenner, Paul Rice.   

Abstract

Toxic industrial chemicals e.g., phosgene, are widely used as reactive intermediates in industrial processes. Inhalation exposure to these chemicals can result in life-threatening acute lung injury (ALI), to which no specific antidote exists. This study aimed to assess the potential benefit of steroids in treating phosgene induced ALI. Anesthetized pigs were instrumented, exposed to phosgene Ct 2000 mg.min.m(-3) (Ct is the product of concentration [mg.m(-3)] x time [min]), and ventilated with intermittent positive pressure ventilation before being randomized to study part 1: treatment with intravenous glucose saline (20 mL) or methylprednisolone (12.5 mg.kg(-1) in 20 mL) 6 h postexposure or study part 2: treatment with inhaled glucose saline (2 mL) or budesonide (2 mL of 0.5 mg.mL(-1) solution) at 1, 6, 12, and 18 h postexposure. Biochemical parameters and animal physiology were monitored to 24 h postexposure. The results show no change in mortality, lung edema, or shunt fraction; however, some beneficial effects on cardiac parameters e.g., stroke volume, left ventricular stroke work, were noted. Steroids were neither beneficial nor detrimental in the treatment of phosgene induced ALI. This study does not support the use of steroids alone as a treatment, but their use in a combined therapy strategy should be investigated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20055070     DOI: 10.7205/milmed-d-09-00050

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  8 in total

Review 1.  The injured lung: clinical issues and experimental models.

Authors:  B J A Jugg; A J Smith; S J Rudall; P Rice
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-01-27       Impact factor: 6.237

2.  An Official American Thoracic Society Workshop Report: Chemical Inhalational Disasters. Biology of Lung Injury, Development of Novel Therapeutics, and Medical Preparedness.

Authors:  Eleanor M Summerhill; Gary W Hoyle; Sven-Eric Jordt; Bronwen J Jugg; James G Martin; Sadis Matalon; Steven E Patterson; David J Prezant; Alfred M Sciuto; Erik R Svendsen; Carl W White; Livia A Veress
Journal:  Ann Am Thorac Soc       Date:  2017-06

3.  Preoperative and intraoperative predictors of postoperative acute respiratory distress syndrome in a general surgical population.

Authors:  James M Blum; Michael J Stentz; Ronald Dechert; Elizabeth Jewell; Milo Engoren; Andrew L Rosenberg; Pauline K Park
Journal:  Anesthesiology       Date:  2013-01       Impact factor: 7.892

4.  Conceptual approaches for treatment of phosgene inhalation-induced lung injury.

Authors:  Wesley W Holmes; Brian M Keyser; Danielle C Paradiso; Radharaman Ray; Devon K Andres; Betty J Benton; Cristin C Rothwell; Heidi M Hoard-Fruchey; James F Dillman; Alfred M Sciuto; Dana R Anderson
Journal:  Toxicol Lett       Date:  2015-11-10       Impact factor: 4.372

5.  Phosgene exposure: a case of accidental industrial exposure.

Authors:  Lewis S Hardison; Edward Wright; Anthony F Pizon
Journal:  J Med Toxicol       Date:  2014-03

Review 6.  Phosgene-induced acute lung injury (ALI): differences from chlorine-induced ALI and attempts to translate toxicology to clinical medicine.

Authors:  Wenli Li; Juergen Pauluhn
Journal:  Clin Transl Med       Date:  2017-06-02

Review 7.  Corticosteroids in Acute Lung Injury: The Dilemma Continues.

Authors:  Daniela Mokra; Pavol Mikolka; Petra Kosutova; Juraj Mokry
Journal:  Int J Mol Sci       Date:  2019-09-25       Impact factor: 5.923

Review 8.  Mechanism of Phosgene-Induced Acute Lung Injury and Treatment Strategy.

Authors:  Qianying Lu; Siyu Huang; Xiangyan Meng; Jianfeng Zhang; Sifan Yu; Junfeng Li; Mingyu Shi; Haojun Fan; Yanmei Zhao
Journal:  Int J Mol Sci       Date:  2021-10-10       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.